These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 6752042)

  • 1. FcIgG receptor-bearing lymphocytes and monoclonal antibody-defined T cell subsets in atopic dermatitis: effect of treatment with thymopoietin pentapeptide (TP-5).
    Strannegård O; Strannegård IL; Kang K; Cooper KD; Hanifin JM
    Int Arch Allergy Appl Immunol; 1982; 69(3):238-44. PubMed ID: 6752042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thymopoietin pentapeptide (TP-5) improves clinical parameters and lymphocyte subpopulations in atopic dermatitis.
    Kang K; Cooper KD; Hanifin JM
    J Am Acad Dermatol; 1983 Mar; 8(3):372-7. PubMed ID: 6339571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of thymopoietin pentapeptide (TP-5) on in vitro and in vivo IgE production by atopic dermatitis cell subsets.
    Cooper KD; Kang K; Hanifin JM
    Diagn Immunol; 1983; 1(3):211-5. PubMed ID: 6388971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppressor cell phenotype deficiency and its restoration by thymopoietin pentapeptide in atopic dermatitis.
    Kang K; Strannegård O; Strannegård IL; Cooper K; Hanifin JM
    Monogr Allergy; 1983; 18():181-5. PubMed ID: 6227816
    [No Abstract]   [Full Text] [Related]  

  • 5. Therapy with thymopoietin pentapeptide (TP-5) in 26 patients with primary immunodeficiencies.
    Aiuti F; Businco L; Fiorilli M; Galli E; Quinti I; Le Moli S; Seminara R; Goldstein G
    Birth Defects Orig Artic Ser; 1983; 19(3):267-72. PubMed ID: 6360238
    [No Abstract]   [Full Text] [Related]  

  • 6. A case of Di George syndrome treated with thymopoietin pentapeptide (TP-5) demonstrating an adherent suppressor cell of lymphocyte function.
    Joffe MI; Sochett E; Pettifor JM; Rabson AR
    J Clin Lab Immunol; 1982 May; 8(1):69-73. PubMed ID: 6212686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone marrow transplantation and thymopoietin pentapeptide treatment in two infants with immunodeficiency with predominant T-cell defects.
    Businco L; Rossi P; Paganelli R; Galli E; DiGilio G; Lulli P; Aiuti F
    Clin Immunol Immunopathol; 1984 Oct; 33(1):123-30. PubMed ID: 6383671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thymopoietin pentapeptide treatment of primary immunodeficiencies.
    Aiuti F; Businco L; Fiorilli M; Galli E; Quinti I; Rossi P; Seminara R; Goldstein G
    Lancet; 1983 Mar; 1(8324):551-4. PubMed ID: 6131256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement of natural killer activity and of T cells after thymopoietin pentapeptide therapy in a patient with severe combined immunodeficiency.
    Fiorilli M; Sirianni MC; Pandolfi F; Quinti I; Tosti U; Aiuti F; Goldstein G
    Clin Exp Immunol; 1981 Aug; 45(2):344-51. PubMed ID: 7032772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of recurrent herpes simplex with thymopoietin-pentapeptide].
    Djawari D; Bolla K; Haneke E
    Dtsch Med Wochenschr; 1984 Mar; 109(13):496-8. PubMed ID: 6368167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thymopentin (TP-5) in the treatment of rheumatoid arthritis.
    Kantharia BK; Goulding NJ; Hall ND; Davies J; Maddison PJ; Bacon PA; Farr M; Wojtulewski JA; Englehart KM; Liyanage SP
    Br J Rheumatol; 1989 Apr; 28(2):118-23. PubMed ID: 2650797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thymopentin therapy reduces the clinical severity of atopic dermatitis.
    Leung DY; Hirsch RL; Schneider L; Moody C; Takaoka R; Li SH; Meyerson LA; Mariam SG; Goldstein G; Hanifin JM
    J Allergy Clin Immunol; 1990 May; 85(5):927-33. PubMed ID: 2185294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of cutaneous T-cell lymphomas with TP-5. Evaluation of the clinical effect in 8 patients.
    Przybilla B; Burg G; Schmoeckel C; Braun-Falco O
    Acta Derm Venereol; 1983; 63(6):524-9. PubMed ID: 6198843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunostimulation by TP-5 in immunocompromised patients and animals--current status of investigation.
    Waymack JP; Alexander JW
    Comp Immunol Microbiol Infect Dis; 1986; 9(2-3):225-32. PubMed ID: 3539496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunologic effects of long-term thymopentin treatment in patients with HIV-induced lymphadenopathy syndrome.
    Silvestris F; Gernone A; Frassanito MA; Dammacco F
    J Lab Clin Med; 1989 Feb; 113(2):139-44. PubMed ID: 2644387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thymopentin treatment of selective IgA deficiency.
    Fiorilli M; Quinti I; Russi G; Seminara R; Ensoli B; Aiuti F
    Surv Immunol Res; 1985; 4 Suppl 1():129-34. PubMed ID: 3898285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stimulation of cellular function by thymopentin (TP-5) in three AIDS patients.
    Mascart-Lemone F; Huygen K; Clumeck N; Brenez D; Bolla K; Duchateau J
    Lancet; 1983 Sep; 2(8352):735-6. PubMed ID: 6193382
    [No Abstract]   [Full Text] [Related]  

  • 18. Abrogation of in vitro suppressor cell activity in adult common variable hypogammaglobulinemia after TP5 treatment.
    Williams RC; Montano JD; Bankhurst AD
    J Lab Clin Med; 1983 Jan; 101(1):152-60. PubMed ID: 6217268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic use of TP5 (thymopoietin 32-36) in sarcoidosis of the skin.
    Thivolet J; Faure M; Nicolas JF; Mauduit G; Claudy A
    Clin Immunol Immunopathol; 1983 Mar; 26(3):350-60. PubMed ID: 6347481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies of thymopoietin pentapeptide (TP5) on experimental tumors. I. TP5 relieves immunosuppression in tumor-bearing mice.
    Lau CY; Wang EY; Goldstein G
    Cell Immunol; 1982 Jan; 66(2):217-32. PubMed ID: 6802504
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.